warrant
potenti
clinic
test
equin
antisarscov
f
requir
evalu
mani
anim
model
possibl
safeti
test
primat
model
studi
evalu
pharmacokinet
toler
immun
kind
antibodi
macaqu
rat
result
show
f
fragment
normal
metabol
inject
anim
gener
physiolog
index
differ
anim
inject
antisarscov
f
salin
howev
mild
inflammatori
respons
local
inject
site
moder
immun
respons
antibodi
success
inject
anim
observ
howev
recov
week
last
inject
antibodi
titr
equin
antisarscov
f
inocul
host
could
detect
week
success
inject
equin
f
consider
safeti
antibodi
use
primat
fact
immun
system
host
motiv
postinject
f
indic
type
antisarscov
antibodi
use
prevent
treatment
sasr
especi
earli
stage
viru
infect
addit
also
provid
preciou
time
combin
use
antisarscov
agent
antivir
drug
vaccin
prevent
treatment
sever
acut
respiratori
syndrom
sar
includ
sever
strategi
includ
vaccin
current
develop
antivir
drug
passiv
transfer
antibodi
antivir
agent
interferon
ribavirin
hiv
proteas
inhibitor
alreadi
shown
promis
result
though
usual
use
empir
sar
outbreak
passiv
immun
appli
prevent
treatment
infecti
diseas
long
time
practic
administ
polyclon
immunoglobulin
hyperimmun
sera
anim
human
origin
histori
effect
virus
provid
anoth
candid
strategi
protect
sarscov
infect
yo
colleagu
found
infus
convalesc
plasma
demonstr
benefici
clinic
outcom
sar
patient
subbarao
et
al
verifi
passiv
transfer
sarscov
specif
antisera
reduc
pulmonari
viral
titr
mice
infect
sarscov
indic
hyperimmun
sera
sarscov
could
protect
viral
infect
equin
antiserum
appli
antivir
regimen
control
rabi
hbv
hiv
infect
gener
equin
antisarscov
f
fragment
shown
neutral
effect
sarscov
vitro
vivo
balbc
mous
model
age
mous
model
golden
hamster
chines
hamster
model
howev
possibl
clinic
applic
antibodi
test
rigor
mani
anim
model
possibl
insur
efficaci
safeti
herein
studi
design
evalu
safeti
pharmacokinet
antibodi
rat
macaqu
order
provid
valuabl
experiment
data
potenti
clinic
use
type
antisarscov
antibodi
sarscov
strain
genbank
access
number
maintain
institut
microbiolog
epidemiolog
amm
china
viral
titr
tissu
cultur
infect
dose
tcid
ml
oper
sarscov
perform
biosafeti
level
laboratori
equin
antisarscov
f
strain
sarscov
endotoxin
free
prepar
describ
previou
public
macaqu
rat
use
studi
provid
anim
centr
academi
militari
medic
scienc
beij
china
macaqu
weigh
kg
fed
individu
among
use
pharmacokinet
studi
safeti
test
approv
anim
experi
obtain
institut
anim
welfar
committe
routin
histolog
assay
done
describ
subbarao
et
al
macaqu
rat
use
pharmacokinet
studi
macaqu
divid
dose
group
receiv
mg
f
per
kilogram
bodi
weight
respect
f
label
specif
activ
ilabel
f
anim
dose
group
iv
inject
mbq
ilabel
f
specif
activ
group
differ
addit
success
administr
group
set
anim
would
iv
inject
mgkg
f
success
indic
time
point
anim
inject
h
inject
bled
via
caudal
vein
total
sera
measur
mgkg
success
administr
group
second
inject
conduct
day
first
inject
anim
inject
iv
everi
week
anim
would
bled
time
point
fourth
inject
total
sera
radioact
measur
rat
iv
inject
mgkg
ilabel
equin
f
specif
radioact
mbqkg
radioact
dose
anim
inject
h
inject
bled
via
caudal
vein
total
sera
measur
describ
macaqu
macaqu
randomli
divid
group
anim
receiv
iv
inject
salin
mg
mlkg
bodi
weight
antisarscov
f
respect
anim
success
inject
day
week
macaqu
group
kill
patholog
individu
organ
tissu
studi
remain
anim
thereaft
observ
week
without
inject
follow
sacrific
patholog
investig
anim
behavior
bodi
weight
bodi
temperatur
electrocardiogram
hematolog
index
hematolog
biochem
indic
urin
index
sera
antibodi
observ
statist
analys
perform
anova
multipl
comparison
scheff
student
ttest
graph
repres
mean
sem
inject
antisarscov
f
macaqu
serum
f
concentr
decreas
gradual
howev
time
point
higher
dose
f
inject
higher
sera
f
concentr
would
retain
fig
iv
inject
mgkg
ilabel
f
ab
termin
halfliv
total
sera
radioact
h
tabl
accord
ratio
inject
dose
antibodi
ratio
growth
rate
area
plasma
concentr
time
curv
auc
h
total
clearanc
rate
clf
significantli
differ
dose
group
indic
linear
pharmacokinet
three
inject
dose
antibodi
studi
tabl
mgkg
bodi
weight
antisarscov
f
iv
inject
success
total
sera
radioact
show
differ
inject
fig
p
n
suggest
multipl
iv
inject
indic
time
point
exert
influenc
concentrationtim
curv
sera
equin
f
total
antisarscov
f
concentr
sera
differ
inject
p
n
tabl
also
signific
differ
pharmacokinet
paramet
inject
tabl
pharmacokinet
paramet
total
sera
radioact
iv
inject
variou
dose
ilabel
f
antibodi
clf
mean
resid
time
mrt
appar
volum
distribut
steadi
state
vss
auc
elimin
rate
constant
kel
tabl
antibodi
show
similar
sera
concentrationtim
cours
rat
inject
mgkg
bodi
weight
antisarscov
f
observ
macaqu
data
shown
correspond
paramet
shown
tabl
antibodi
rat
h
total
radioact
tabl
higher
seen
macaqu
tabl
gener
physiolog
index
differ
anim
inject
antisarscov
f
salin
bodi
weight
bodi
temperatur
electrocardiogram
hematolog
biochem
index
normal
howev
antibodyinject
anim
develop
skin
erythema
radiu
cm
inject
site
success
inject
also
two
week
last
inject
antibodi
equin
f
could
detect
macaqu
sera
highest
antif
titr
observ
week
last
inject
tabl
weight
spleen
antibodyinject
anim
greater
control
mean
weight
spleen
g
control
macaqu
g
anim
inject
mgkg
antibodi
g
anim
inject
mgkg
antibodi
howev
week
last
inject
weight
inject
anim
spleen
differ
control
weight
organ
normal
level
data
shown
organ
also
examin
patholog
last
inject
four
anim
group
sacrif
organ
anim
investig
spleen
lymph
node
antibodyinject
anim
signific
pathomorpholog
chang
compar
control
anim
fig
mgkg
group
spleen
display
patholog
chang
correl
inject
equin
f
ab
fig
c
mild
lymph
follicular
hyperplasia
expand
germin
center
prolifer
follicular
dendrit
cell
fdc
macrophag
splenic
cord
mild
moder
plasma
cell
prolifer
occur
patholog
chang
lymph
node
similar
observ
spleen
immun
reaction
overt
fig
g
appar
lymph
follicular
hyperplasia
cortic
part
germin
center
expand
macrophag
prolifer
show
activ
phagocytosi
full
erythrocyt
hemosiderin
organ
show
signific
patholog
chang
data
shown
inject
site
anim
inject
equin
antisarscov
f
show
patholog
chang
dermi
subcutan
tissu
antibodyinject
immunostimul
equin
f
macaqu
immun
organ
macaqu
receiv
success
inject
mgkg
bodi
weight
equin
antisarscov
f
everyday
week
without
recoveri
last
inject
panel
spleen
monkey
inject
salin
panel
b
c
spleen
success
inject
monkey
panel
spleen
monkey
receiv
success
inject
recoveri
last
inject
panel
e
lymph
node
monkey
inject
salin
panel
f
g
lymph
node
success
inject
anim
panel
h
lymph
node
monkey
receiv
success
inject
recoveri
last
inject
panel
inject
site
salineinject
control
macaqu
panel
j
inject
site
macaqu
receiv
success
inject
panel
k
inject
site
anim
inject
success
recoveri
last
inject
stain
method
magnif
photo
indic
anim
display
partial
angiolysi
vessel
wall
prolifer
thicken
tunica
intima
collagen
fiber
hyalin
focal
fibrinoid
necrosi
thrombosi
lumen
blood
vessel
compar
salin
control
fig
j
recoveri
week
success
inject
immun
reaction
spleen
lymph
node
resolv
fig
h
organ
look
normal
inject
site
small
vessel
show
thrombu
organ
mani
neutrophil
granulocyt
wall
fig
mgkg
group
show
patholog
chang
secondari
lymphoid
organ
similar
observ
mgkg
group
anim
display
less
plasma
cell
prolifer
data
shown
previous
show
equin
antisarscov
f
prevent
infect
cultur
vero
cell
variou
anim
model
includ
adult
age
balbc
mous
model
golden
syria
hamster
chines
hamster
model
furthermor
antibodi
provid
therapeut
protect
sarscovinfect
vero
cell
anim
model
howev
possibl
heterogen
antibodi
might
evok
strong
host
immun
respons
may
inhibit
applic
clinic
set
thu
develop
human
human
antibodi
sarscov
theoret
ideal
strategi
prevent
infect
would
recogn
self
compon
human
host
would
elicit
immun
respons
host
reason
consider
difficulti
find
immun
human
donor
risk
relat
use
human
blood
product
human
human
monoclon
antibodi
sarscov
compon
develop
exhibit
effect
prevent
role
sarscov
infect
vitro
vivo
nevertheless
major
obstacl
applic
mab
clinic
yield
mab
product
howev
heterolog
antibodi
exampl
equin
igg
advantag
respect
furthermor
one
theoret
potenti
advantag
polyclon
igg
broader
antigen
coverag
lower
likelihood
emerg
escap
mutant
although
theoret
advantag
equin
antisarscov
f
studi
addit
heterolog
specif
igg
decreas
prepar
f
fragment
cut
fc
fragment
thu
f
higher
specif
neutral
activ
complet
igg
molecul
mean
smaller
quantiti
f
would
need
neutral
viru
would
reduc
possibl
immun
respons
f
although
skin
test
hypersensit
possibl
desensit
may
still
necessari
practic
studi
investig
pharmacolog
safeti
equin
antisasrcov
f
macaqu
rat
assay
pharmacokinet
equin
antisarscov
f
macaqu
rat
verifi
safeti
use
type
antibodi
administ
anim
although
auc
f
concentr
higher
higher
amount
agent
administ
mrt
h
clf
vss
h
kel
differ
dose
inject
mgkg
vs
mgkg
vs
mgkg
respect
fig
tabl
importantli
inject
success
four
time
pharmacokinet
paramet
inject
antibodi
inject
time
point
fig
tabl
pharmokinet
data
suggest
f
fragment
normal
metabol
inject
anim
investig
toler
immun
host
inject
f
macaqu
gener
physiolog
index
signific
differ
success
inject
anim
control
suggest
good
toler
anim
agent
howev
realli
observ
local
patholog
chang
inject
site
spleen
lymph
node
host
observ
anim
inject
equin
antisarscov
f
show
mild
inflammatori
respons
local
site
inject
weight
spleen
lymph
node
inject
anim
increas
moder
compar
control
morpholog
observ
indic
moder
immun
respons
spleen
lymph
node
inject
anim
administ
equin
antisarscov
f
fragment
howev
morpholog
chang
secondari
immun
organ
relat
inject
f
disappear
recoveri
last
inject
morpholog
data
indic
host
toler
success
inject
f
correspond
morpholog
chang
lymph
organ
success
inject
f
antibodi
inject
equin
f
detect
experiment
anim
week
postsuccess
inject
even
detect
week
recoveri
success
inject
everyday
data
indic
heterogen
antibodi
inde
elicit
immun
respons
inocul
host
nevertheless
experiment
anim
die
antibodi
inject
motiv
host
secondari
lymphoid
organ
spleen
lymph
node
recov
week
last
inject
indic
good
toler
host
antibodi
inject
addit
host
antif
antibodi
appear
week
f
administr
enough
time
equin
antibodi
exert
protect
effect
earli
stage
sarscov
infect
shown
previou
studi
type
antibodi
sever
anim
model
thu
produc
mark
effect
largescal
sar
outbreak
provid
enough
time
combin
applic
antisarscov
agent
antivir
drug
vaccin
